[HTML][HTML] Overall survival and long-term safety of nivolumab (anti–programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated …

SN Gettinger, L Horn, L Gandhi, DR Spigel… - Journal of clinical …, 2015 - ncbi.nlm.nih.gov
SN Gettinger, L Horn, L Gandhi, DR Spigel, SJ Antonia, NA Rizvi, JD Powderly, RS Heist…
Journal of clinical oncology, 2015ncbi.nlm.nih.gov
Purpose Programmed death 1 is an immune checkpoint that suppresses antitumor immunity.
Nivolumab, a fully human immunoglobulin G4 programmed death 1 immune checkpoint
inhibitor antibody, was active and generally well tolerated in patients with advanced solid
tumors treated in a phase I trial with expansion cohorts. We report overall survival (OS),
response durability, and long-term safety in patients with non–small-cell lung cancer
(NSCLC) receiving nivolumab in this trial.
Abstract
Purpose
Programmed death 1 is an immune checkpoint that suppresses antitumor immunity. Nivolumab, a fully human immunoglobulin G4 programmed death 1 immune checkpoint inhibitor antibody, was active and generally well tolerated in patients with advanced solid tumors treated in a phase I trial with expansion cohorts. We report overall survival (OS), response durability, and long-term safety in patients with non–small-cell lung cancer (NSCLC) receiving nivolumab in this trial.
ncbi.nlm.nih.gov